[HTML][HTML] Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications
S Wu, R Li, Y Jiang, J Yu, J Zheng, Z Li, M Li… - Biomedicine & …, 2023 - Elsevier
The types of urothelial carcinoma (UC) include urothelial bladder cancer and upper tract
urothelial carcinoma. Current diagnostic techniques cannot meet the needs of patients …
urothelial carcinoma. Current diagnostic techniques cannot meet the needs of patients …
Surface-enhanced Raman scattering-based strategies for tumor markers detection: A review
Y Wu, Y Wang, T Mo, Q Liu - Talanta, 2024 - Elsevier
The presence of malignant tumors poses a significant threat to people's life and well-being.
As biochemical parameters indicate the occurrence and development of tumors, tumor …
As biochemical parameters indicate the occurrence and development of tumors, tumor …
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
TB Dorff, MS Blanchard, LN Adkins, L Luebbert… - Nature Medicine, 2024 - nature.com
Despite recent therapeutic advances, metastatic castration-resistant prostate cancer
(mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies have …
(mCRPC) remains lethal. Chimeric antigen receptor (CAR) T cell therapies have …
Modern Kidney-Sparing Management of Upper Tract Urothelial Carcinoma
A Ghoreifi, R Sari Motlagh, G Fuchs - Cancers, 2023 - mdpi.com
Simple Summary Upper tract urothelial carcinoma (UTUC) is a lethal cancer of the urinary
tract. Radical nephroureterectomy with bladder cuff excision is the gold standard for the …
tract. Radical nephroureterectomy with bladder cuff excision is the gold standard for the …
Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery
SN Shishido, E Lin, N Nissen, G Courcoubetis… - npj Precision …, 2024 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of less than 10%
due to its late diagnosis, rapid metastasis, and chemotherapeutic resistance. For a small …
due to its late diagnosis, rapid metastasis, and chemotherapeutic resistance. For a small …
Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard?
I Duquesne, M Abou Chakra, L Hage… - Expert Review of …, 2023 - Taylor & Francis
Introduction Liquid biopsies are used for the detection of tumor-specific elements in body
fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder …
fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder …
Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsy
SN Shishido, D Suresh, G Courcoubetis, B Ye, E Lin… - BJC reports, 2024 - nature.com
Background Cancer becomes lethal as it spreads from the primary site to the rest of the
body. Circulating tumor cells (CTCs) are biomarkers of disease progression and have been …
body. Circulating tumor cells (CTCs) are biomarkers of disease progression and have been …
Circulation of rare events in the liquid biopsy for early detection of lung mass lesions
K Resnick, A Shah, J Mason, P Kuhn, J Nieva… - Thoracic …, 2024 - Wiley Online Library
Background Lung cancer screening with low‐dose computed tomography (CT) scans
(LDCT) has reduced mortality for patients with high‐risk smoking histories, but it has …
(LDCT) has reduced mortality for patients with high‐risk smoking histories, but it has …
A urine-based liquid biopsy for detection of upper tract urothelial carcinoma: a self-matched study
W Wei, P Fan, Z Zhang, D Wu, J Liu, L Wang, X Duan… - BMC cancer, 2024 - Springer
Background To establish the pathological diagnosis of UTUC before treatment is profitable.
At present, the conventional pathological diagnostic methods have certain problems …
At present, the conventional pathological diagnostic methods have certain problems …
[HTML][HTML] Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
SN Shishido, O Hart, S Jeong, A Moriarty… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment
of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene …
of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene …